Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

eutropenia. Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Five percent or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue, grade 3 or 4 infections and pulmonary/respiratory grade 3 or 4 toxicities.

About Satraplatin

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Platinum-based drugs are a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. All platinum drugs currently on the market require intravenous administration. Satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home.

A Phase 3 registrational trial, called SPARC, is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer whose prior chemotherapy has failed. Data from the trial on progression-free survival and on safety have been presented at recent medical conferences. In accordance with the recommendation of the independent Data Monitoring Board for the SPARC trial, patients who have not progressed continue to be treated and all patients will be followed for overall survival.

GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. Pharmion has indicated it expects to complete the Marketing Authorization Application (MAA) for satraplatin for Europe in the second quarter of 2007. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002.

Satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in c
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/30/2014)... 30, 2014 This study provides an ... informatics solutions including nuclear imaging informatics, PET imaging ... study assesses the size of the market based ... and projects future growth based on the current ... taking place in the broader markets for imaging ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the Asia ... China , India , ... rate through 2023. Dental implant procedure volumes will grow as physicians ... Other key findings from Decision Resources Group,s coverage of ... , Dental implant penetration: Penetration of dental implants among ...
(Date:9/30/2014)... , Sept. 30, 2014 A study using ... offered a new look at the composition of carotid ... physicians understand and treat the disease, a leading cause ... Baptist Health Lexington between September 2010 and May 2012, ... Journal of the American College of Cardiology (JACC) ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , PHILADELPHIA, ... Dr. Michael J. McKelvey, the Company,s President and CEO, and Keith ... present at the 21st Annual Piper Jaffray Health Care Conference at ... New York. , Interested parties may access the presentation by visiting ...
... , , WEST PALM BEACH, Fla., ... Americans, especially the 27 million living with untreated hearing loss ... Cindy Beyer. , Dr. Beyer, senior vice president of HearUSA (Amex: ... hearing aids companies, said studies have linked hearing loss to ...
Cached Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3
(Date:10/1/2014)... October 01, 2014 Phoseon Technology, the ... continues to expand the business worldwide. This rapid growth ... additional capacity for manufacturing efforts. The company has experienced ... five years and expects this growth to continue in ... technology gains worldwide adoption. , “We are very ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Generic drug ... retail generics increasing in price in the last 12 ... Inc.’s (AIS) Drug Benefit News (DBN) interviewed a plan ... means for pharmacies and health plans. , “When ... rising generic acquisition costs, these cost increases squeeze pharmacies’ ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 2Health News:Rising Generic Drug Prices Affect Pharmacies, Insurers Alike, Reports AIS Newsletter 3
... use of limited supplies of flu vaccine, according to research ... suggests that, used to support other control measures, this could ... swine flu. As the World Health Organization declares a ... to control the spread of the disease. These measures include ...
... , WEYMOUTH, Mass., June 17 Registration is underway for ... of Weymouth. Sessions begin on Monday, July 6 at ... , THE CPAP SUCCESS GROUP is designed to help struggling ... learn how to use CPAP more easily and effectively by learning ...
... hormone formulations provide significant pharmacological responses , , DALLAS, ... (OTC Bulletin Board: ACCP) ... two biopharmaceutical companies for its Cobalamin(TM) Oral Drug ... both companies plan to evaluate Access, Oral Insulin ...
... Lower doses safe and effective after heart attack and stroke ... pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack ... or suffer from unstable angina, a new trial shows. , ... involved in blood clotting. In earlier studies, the drug was ...
... Recognizes Entrepreneurial Excellence in Health and Life Sciences Category , ... -- Accuray Incorporated (Nasdaq: ARAY ), a ... Euan Thomson, Ph.D., the company,s president and CEO, received the ... the Health and Life Sciences category in Northern California. ...
... Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) ... agreement with Handok Pharmaceuticals Co., Ltd. ("Handok"), the ... under which Echo granted Handok rights to develop, ... ("Symphony") for painless, needle-free, transdermal, continuous glucose monitoring ...
Cached Medicine News:Health News:Vaccinating children may be effective at helping control spread of influenza, experts say 2Health News:Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 3Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 4
... kit features a patented Per-fit™ flexible PVC ... a low-profile cuff specifically designed to reduce ... the patients anatomy. The kit s unique ... tube snugly, allowing for an easier transition ...
... Self-contained kits provide convenience and cost ... tracheostomy care trays offer a variety of ... and management of the tracheostomized patient. , ... trays, and trays with disposable inner cannula ...
Disposable tracheostomy care tray....
... For Your Tracheostomy Care Needs, ,Each ... the latest components for efficient and convenient ... Designed by clinicians, these latex-free trays provide ... and caregiver. All of our trays also ...
Medicine Products: